Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
IL-6阻断联合检查点抑制的相关生物标志物
基本信息
- 批准号:10208830
- 负责人:
- 金额:$ 59.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-02 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Acute-Phase ProteinsAftercareAntigen-Presenting CellsBiological AssayBiological MarkersBiological Response ModifiersBlocking AntibodiesBlood CellsBlood specimenC-reactive proteinCell physiologyCellsChargeCombination immunotherapyConsultDataDendritic CellsDoseEvaluationFlow CytometryGene Expression ProfileGenetic TranscriptionImmuneImmunohistochemistryImmunosuppressionImmunotherapyInstitutional Review BoardsInterleukin 6 ReceptorInterleukin-6LiverMALDI-TOF Mass SpectrometryMass Spectrum AnalysisMetastatic MelanomaNivolumabOutcomePatientsPeripheral Blood Mononuclear CellPhenotypePopulationProteinsResistanceResolutionRoleSamplingSerumT-LymphocyteToxic effectTumor Markersanti-PD1 antibodiesbasecheckpoint inhibitionchemotherapyclinical efficacycytokinedesignimmune checkpoint blockadeimmune-related adverse eventsimprovedinsightipilimumabmacrophagemelanomaperipheral bloodphase 2 studyphase II trialprimary endpointprognosticprogrammed cell death ligand 1responsesingle-cell RNA sequencingtherapy resistanttocilizumabtranscriptome sequencingtrial designtumor
项目摘要
This proposal is based on an analysis of serum from melanoma patients treated with the PD-1 antibody
nivolumab (NIVO) showing that high levels of IL-6 and acute phase reactants (APP) induced by IL-6 like C-
reactive protein (CRP) are associated with poor survival. We hypothesize that CRP and other APP induced
by IL-6 are associated with resistance to checkpoint inhibition in melanoma, and are immunosuppressive.
This is supported by our preliminary data showing that CRP levels are associated with low response rates
and short survival with NIVO or ipilimumab (IPI). IL-6 promotes the synthesis of CRP and other APPs from
the liver, and its levels are also associated with low response rates, short survival and therapeutic resistance
in patients receiving NIVO, IPI or combination immune checkpoint blockade (ICB). Patients with low IL-6 at
baseline or after treatment with ICB have high response rates and long survivals. To overcome the immune
suppression observed with CRP and reverse ICB resistance associated with high IL-6, we will add the IL-6
receptor blocking antibody tocilizumab to IPI and NIVO in patients with metastatic melanoma. Our overarching
hypothesis is that levels of IL-6 and CRP in baseline serum and other biomarkers in serum, PBMCs and tumor
will predict efficacy and toxicity in a phase II trial of IPI/NIVO with tocilizumab and that IL-6 blockade will
augment the efficacy of, and reduce toxicity from combined ICB. These biomarkers will provide insight into
host/tumor mediators of ICB and help direct patients to the most effective immunotherapy based on their
baseline and on-treatment levels of IL-6/CRP and other biomarkers. Co-primary endpoints of the trial include
best overall response rate and toxicity since IL-6 blockade has also been shown to reduce immune-related
adverse events with immunotherapy. A Simon two-stage design trial will include 67 patients that will receive
the triple combination and will be supported by BMS. In this proposal, we wish to support the correlative
marker studies based on that phase II trial. Analyses of the serum, tumor and peripheral blood will be carried
out to establish biomarkers of efficacy and toxicity and help understand the basis for resistance to combination
ICB in melanoma based on three specific aims: 1. To determine if baseline levels, or on-treatment changes
in a serum mass spectrometry-MALDI-TOF protein signature and acute phase reactants and cytokines are
associated with response and toxicity in a phase II trial of IPI/NIVO with the IL-6 receptor blocking antibody
tocilizumab; 2. To determine if baseline or on-treatment changes in peripheral blood and tumor T cell
phenotype and function assessed by multi-parameter flow cytometry, Ab-Seq and IsoLight assays, peripheral
blood dendritic cell phenotype and function and tumor class I and II expression, PD-L1 levels and RNA seq
signatures are associated with response and toxicity in a phase II study of IPI/NIVO with tocilizumab; and 3.
To integrate the serum, peripheral blood and tumor biomarkers of aims 1 and 2 to assess if a consolidated
signature is associated with response and toxicity in a phase II study of IPI/NIVO with tocilizumab.
该提案基于对接受 PD-1 抗体治疗的黑色素瘤患者血清的分析
nivolumab (NIVO) 显示高水平的 IL-6 和急性期反应物 (APP) 由 IL-6 诱导,如 C-
反应蛋白(CRP)与较差的生存率相关。我们假设 CRP 和其他 APP 诱导
IL-6 的作用与黑色素瘤中检查点抑制的抵抗有关,并且具有免疫抑制作用。
我们的初步数据证明了这一点,表明 CRP 水平与低反应率相关
NIVO 或 ipilimumab (IPI) 的生存期较短。 IL-6促进CRP和其他APP的合成
肝脏,其水平也与低反应率、短生存期和治疗耐药性相关
接受 NIVO、IPI 或联合免疫检查点阻断 (ICB) 的患者。 IL-6 水平较低的患者
基线或 ICB 治疗后有较高的缓解率和较长的生存期。为了克服免疫
观察到的 CRP 抑制和与高 IL-6 相关的逆转 ICB 耐药性,我们将添加 IL-6
转移性黑色素瘤患者中针对 IPI 和 NIVO 的受体阻断抗体托珠单抗。我们的首要任务
假设基线血清中的 IL-6 和 CRP 水平以及血清、PBMC 和肿瘤中的其他生物标志物水平
将在使用托珠单抗的 IPI/NIVO II 期试验中预测疗效和毒性,并且 IL-6 阻断将
增强联合 ICB 的功效并降低其毒性。这些生物标志物将提供深入了解
ICB 的宿主/肿瘤介质,并根据患者的情况帮助指导患者接受最有效的免疫治疗
IL-6/CRP 和其他生物标志物的基线和治疗中水平。试验的共同主要终点包括
自IL-6阻断以来最佳的总体缓解率和毒性也被证明可以减少免疫相关的
免疫治疗的不良事件。 Simon 的两阶段设计试验将包括 67 名患者,他们将接受
三重组合将得到BMS的支持。在本提案中,我们希望支持相关的
基于该 II 期试验的标志物研究。将进行血清、肿瘤和外周血的分析
建立功效和毒性的生物标志物,并帮助了解组合耐药性的基础
黑色素瘤中的 ICB 基于三个具体目标: 1. 确定基线水平或治疗中是否发生变化
在血清质谱-MALDI-TOF 蛋白质特征和急性期反应物和细胞因子中
与使用 IL-6 受体阻断抗体的 IPI/NIVO II 期试验中的反应和毒性相关
托珠单抗; 2. 确定外周血和肿瘤 T 细胞的基线或治疗中是否发生变化
通过多参数流式细胞术、Ab-Seq 和 IsoLight 检测、外周血检测评估表型和功能
血液树突状细胞表型和功能以及肿瘤 I 类和 II 类表达、PD-L1 水平和 RNA seq
在 IPI/NIVO 与托珠单抗的 II 期研究中,特征与反应和毒性相关;和 3.
整合目标 1 和 2 的血清、外周血和肿瘤生物标志物,以评估是否可以整合
在 IPI/NIVO 与托珠单抗的 II 期研究中,特征与反应和毒性相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey S Weber其他文献
How Far We've Come.
我们已经走了多远。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:2.2
- 作者:
Mario Sznol;Jeffrey S Weber - 通讯作者:
Jeffrey S Weber
Jeffrey S Weber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey S Weber', 18)}}的其他基金
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
IL-6阻断联合检查点抑制的相关生物标志物
- 批准号:
10441494 - 财政年份:2020
- 资助金额:
$ 59.34万 - 项目类别:
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
IL-6阻断联合检查点抑制的相关生物标志物
- 批准号:
10657374 - 财政年份:2020
- 资助金额:
$ 59.34万 - 项目类别:
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
IL-6阻断联合检查点抑制的相关生物标志物
- 批准号:
10039468 - 财政年份:2020
- 资助金额:
$ 59.34万 - 项目类别:
Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma
转移性黑色素瘤中 PD-1 和 CTLA-4 抗体的合理测序
- 批准号:
8483472 - 财政年份:2013
- 资助金额:
$ 59.34万 - 项目类别:
Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma
转移性黑色素瘤中 PD-1 和 CTLA-4 抗体的合理测序
- 批准号:
8853178 - 财政年份:2013
- 资助金额:
$ 59.34万 - 项目类别:
Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma
转移性黑色素瘤中 PD-1 和 CTLA-4 抗体的合理测序
- 批准号:
8690800 - 财政年份:2013
- 资助金额:
$ 59.34万 - 项目类别:
Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma
转移性黑色素瘤中 PD-1 和 CTLA-4 抗体的合理测序
- 批准号:
9228625 - 财政年份:2013
- 资助金额:
$ 59.34万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 59.34万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 59.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 59.34万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 59.34万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 59.34万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 59.34万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 59.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 59.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 59.34万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 59.34万 - 项目类别: